Patents by Inventor George Fromm

George Fromm has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • VSIG8-based chimeric proteins
    Patent number: 11192933
    Abstract: The present invention relates, in part, to chimeric proteins which include the extracellular domain of V-set and immunoglobulin domain-containing protein 8 (VSIG8) and their use in the treatment of diseases, such as immunotherapies for cancer and/or inflammatory diseases.
    Type: Grant
    Filed: February 27, 2018
    Date of Patent: December 7, 2021
    Assignee: Shattuck Labs, Inc.
    Inventors: Taylor Schreiber, George Fromm, Suresh De Silva
  • VSIG8-based chimeric proteins
    Patent number: 11192934
    Abstract: The present invention relates, in part, to chimeric proteins which include the extracellular domain of V-set and immunoglobulin domain-containing protein 8 (VSIG8) and their use in the treatment of diseases, such as immunotherapies for cancer and/or inflammatory diseases.
    Type: Grant
    Filed: October 28, 2019
    Date of Patent: December 7, 2021
    Assignee: Shattuck Labs, Inc.
    Inventors: Taylor Schreiber, George Fromm, Suresh De Silva
  • COMBINATION THERAPIES
    Publication number: 20210324041
    Abstract: The present invention relates to, inter alia, combinations of compositions which include chimeric proteins that find use in methods for treating disease, such as immunotherapies for cancer and autoimmunity.
    Type: Application
    Filed: August 29, 2019
    Publication date: October 21, 2021
    Inventors: Taylor SCHREIBER, George FROMM, Suresh DE SILVA
  • COMBINATION THERAPIES COMPRISING PD-1-BASED CHIMERIC PROTEINS
    Publication number: 20210309744
    Abstract: The present invention relates to, inter alia, combinations of compositions which include chimeric proteins that find use in methods for treating disease, such as immunotherapies for cancer and autoimmunity.
    Type: Application
    Filed: August 29, 2019
    Publication date: October 7, 2021
    Inventors: Taylor SCHREIBER, George FROMM, Suresh DE SILVA
  • Heterodimeric proteins for modulating gamma delta T cells
    Patent number: 11098093
    Abstract: The present technology relates, inter alia, to compositions and methods, including heterodimeric proteins that find use in the treatment of disease, such as immunotherapies for cancer and autoimmunity.
    Type: Grant
    Filed: January 13, 2020
    Date of Patent: August 24, 2021
    Assignee: Shattuck Labs, Inc.
    Inventors: Taylor Schreiber, George Fromm, Suresh De Silva
  • HETERODIMERIC PROTEINS AND USES THEREOF
    Publication number: 20210214409
    Abstract: The present invention relates, inter alia, to compositions and methods, including heterodimeric proteins that find use in the treatment of disease, such as immunotherapies for cancer and autoimmunity.
    Type: Application
    Filed: March 24, 2021
    Publication date: July 15, 2021
    Inventors: Taylor SCHREIBER, George FROMM, Suresh DE SILVA
  • COMBINATION THERAPIES COMPRISING TIM-3-BASED CHIMERIC PROTEINS
    Publication number: 20210179689
    Abstract: The present invention relates, inter alia, to compositions and methods, including chimeric proteins comprising an extracellular domain of T-cell immunoglobulin mucin receptor 3 (TIM-3) and an extracellular domain of CD40 Ligand (CD40L) or an extracellular domain of OX40 Ligand (OX40L) that find use in the treatment of disease, such as cancer.
    Type: Application
    Filed: August 29, 2019
    Publication date: June 17, 2021
    Inventors: Taylor SCHREIBER, George FROMM, Suresh DE SILVA
  • Heterodimeric proteins and uses thereof
    Patent number: 10995127
    Abstract: The present invention relates, inter alia, to compositions and methods, including heterodimeric proteins that find use in the treatment of disease, such as immunotherapies for cancer and autoimmunity.
    Type: Grant
    Filed: September 16, 2019
    Date of Patent: May 4, 2021
    Assignee: Shattuck Labs, Inc.
    Inventors: Taylor Schreiber, George Fromm, Suresh De Silva
  • Heterodimeric proteins for modulating gamma delta T cells
    Patent number: 10988517
    Abstract: The present technology relates, inter alia, to compositions and methods, including heterodimeric proteins that find use in the treatment of disease, such as immunotherapies for cancer and autoimmunity.
    Type: Grant
    Filed: June 3, 2020
    Date of Patent: April 27, 2021
    Assignee: Shattuck Labs, Inc.
    Inventors: Taylor Schreiber, George Fromm, Suresh De Silva
  • TIGIT- and light-based chimeric proteins
    Patent number: 10927159
    Abstract: The present invention relates, inter alia, to compositions and methods, including TIGIT- and/or LIGHT-based chimeric proteins that find use in the treatment of disease, such as cancer and an inflammatory disease.
    Type: Grant
    Filed: September 10, 2020
    Date of Patent: February 23, 2021
    Assignee: Shattuck Labs, Inc.
    Inventors: Taylor Schreiber, George Fromm, Suresh De Silva
  • FLT3L-BASED CHIMERIC PROTEINS
    Publication number: 20210046116
    Abstract: The present invention relates, inter alia, to compositions and methods, including chimeric proteins comprising an extracellular domain of FMS like tyrosine kinase 3 ligand (FLT3L) and an extracellular domain of a Type II transmembrane protein that find use in the treatment of disease, such as cancer.
    Type: Application
    Filed: August 13, 2020
    Publication date: February 18, 2021
    Inventors: Taylor SCHREIBER, George FROMM, Suresh DE SILVA
  • TIGIT- and light-based chimeric proteins
    Patent number: 10899817
    Abstract: The present invention relates, inter alia, to compositions and methods, including TIGIT- and/or LIGHT-based chimeric proteins that find use in the treatment of disease, such as cancer and an inflammatory disease.
    Type: Grant
    Filed: April 24, 2020
    Date of Patent: January 26, 2021
    Assignee: Shattuck Labs, Inc.
    Inventors: Taylor Schreiber, George Fromm, Suresh De Silva
  • VECTOR CO-EXPRESSING VACCINE AND COSTIMULATORY MOLECULES
    Publication number: 20210000945
    Abstract: Compositions and methods for co-expressing a secretable vaccine protein (such as gp96-Ig) and T-cell co-stimulatory molecules from a single vector, among others, are provided herein. Materials and methods for using gp96-Ig vaccination and T-cell co-stimulation to treat a clinical condition (e.g., cancer) in a subject also are provided.
    Type: Application
    Filed: July 24, 2020
    Publication date: January 7, 2021
    Inventors: Taylor SCHREIBER, George FROMM
  • NK CELL-DIRECTED CHIMERIC PROTEINS
    Publication number: 20200399344
    Abstract: The present invention relates, inter alia, to compositions and methods, including chimeric proteins comprising an extracellular domain of a Type I transmembrane protein or a portion of a membrane-anchored extracellular protein and a portion of the extracellular domain of a Type II transmembrane protein, wherein the Type II transmembrane protein is naturally expressed on the surface of a Natural Killer (NK) cell that find use in the treatment of disease, such as cancer and viral infections.
    Type: Application
    Filed: September 10, 2020
    Publication date: December 24, 2020
    Inventors: Taylor SCHREIBER, Casey SHUPTRINE, George FROMM, Suresh DE SILVA
  • TIGIT- AND LIGHT-BASED CHIMERIC PROTEINS
    Publication number: 20200399342
    Abstract: The present invention relates, inter alia, to compositions and methods, including TIGIT- and/or LIGHT-based chimeric proteins that find use in the treatment of disease, such as cancer and an inflammatory disease.
    Type: Application
    Filed: September 10, 2020
    Publication date: December 24, 2020
    Inventors: Taylor SCHREIBER, George FROMM, Suresh DE SILVA
  • HETERODIMERIC PROTEINS FOR MODULATING GAMMA DELTA T CELLS
    Publication number: 20200308238
    Abstract: The present technology relates, inter alia, to compositions and methods, including heterodimeric proteins that find use in the treatment of disease, such as immunotherapies for cancer and autoimmunity.
    Type: Application
    Filed: June 3, 2020
    Publication date: October 1, 2020
    Inventors: Taylor SCHREIBER, George FROMM, Suresh DE SILVA
  • FLT3L-based chimeric proteins
    Patent number: 10780121
    Abstract: The present invention relates, inter alia, to compositions and methods, including chimeric proteins comprising an extracellular domain of FMS like tyrosine kinase 3 ligand (FLT3L) and an extracellular domain of a Type II transmembrane protein that find use in the treatment of disease, such as cancer.
    Type: Grant
    Filed: September 13, 2019
    Date of Patent: September 22, 2020
    Assignee: Shattuck Labs, Inc.
    Inventors: Taylor Schreiber, George Fromm, Suresh De Silva
  • Vector co-expressing vaccine and costimulatory molecules
    Patent number: 10780161
    Abstract: Compositions and methods for co-expressing a secretable vaccine protein (such as gp96-Ig) and T-cell co-stimulatory molecules from a single vector, among others, are provided herein. Materials and methods for using gp96-Ig vaccination and T-cell co-stimulation to treat a clinical condition (e.g., cancer) in a subject also are provided.
    Type: Grant
    Filed: June 25, 2018
    Date of Patent: September 22, 2020
    Assignee: Heat Biologics, Inc.
    Inventors: Taylor Schreiber, George Fromm
  • TIGIT- AND LIGHT-BASED CHIMERIC PROTEINS
    Publication number: 20200283496
    Abstract: The present invention relates, inter alia, to compositions and methods, including TIGIT- and/or LIGHT-based chimeric proteins that find use in the treatment of disease, such as cancer and an inflammatory disease.
    Type: Application
    Filed: April 24, 2020
    Publication date: September 10, 2020
    Inventors: Taylor SCHREIBER, George FROMM, Suresh DE SILVA
  • Vector co-expressing vaccine and costimulatory molecules
    Patent number: 10758611
    Abstract: Compositions and methods for co-expressing a secretable vaccine protein (such as gp96-Ig) and T-cell co-stimulatory molecules from a single vector, among others, are provided herein. Materials and methods for using gp96-Ig vaccination and T-cell co-stimulation to treat a clinical condition (e.g., cancer) in a subject also are provided.
    Type: Grant
    Filed: June 25, 2018
    Date of Patent: September 1, 2020
    Assignee: Heat Biologics, Inc.
    Inventors: Taylor Schreiber, George Fromm